Top Suppliers:I want be here



585543-15-3

585543-15-3 structure
585543-15-3 structure
  • Name: Losmapimod
  • Chemical Name: 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
  • CAS Number: 585543-15-3
  • Molecular Formula: C22H26FN3O2
  • Molecular Weight: 383.459
  • Catalog: Biochemical Inhibitor Mitogen-activated protein kinase (MAPK) P38 MAPK inhibitor
  • Create Date: 2018-12-18 14:08:27
  • Modify Date: 2024-01-20 14:08:07
  • Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.

Name 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
Synonyms UNII-F2DQF16BXE
6-[5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)nicotinamide
Losmapimod
3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-
Description Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.
Related Catalog
Target

pKi: 8.1 (p38α), 7.6 (p38β)

In Vivo In the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β)[1].
Animal Admin Male SHR-SPs (n=70) are randomly assigned according to body weight into five groups (n=14 per group): normal diet controls (ND), high salt-fat diet controls (SFD), SFD + GSK-AHAB (1.2 mg/kg/day), and SFD + GSK-AHAB (12 mg/kg/day) and SFD + rofecoxib (18 mg/kg/day). All drugs are administered in the diet by mixing with the SFD. A subgroup of animals from each group (n=6 per group) are anesthetized with isoflurane and surgically instrumented with radiotelemetry units for the conscious measurement of mean arterial blood pressure and heart rate. These animals are allowed to recover for at least 7 days before the start of the study.
References

[1]. Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70.

[2]. Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.

Density 1.2±0.1 g/cm3
Boiling Point 529.4±50.0 °C at 760 mmHg
Molecular Formula C22H26FN3O2
Molecular Weight 383.459
Flash Point 274.0±30.1 °C
Exact Mass 383.200897
PSA 78.07000
LogP 3.30
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.582
Storage condition -20℃